Skip to main content

Rheums manage #RA. But patients have to manage RA and their lives - I wish we could provide better guidance to our patie

Social Author Name
Dr. John Cush
Tweet Content
Rheums manage #RA. But patients have to manage RA and their lives - I wish we could provide better guidance to our patients about Life with RA. Heres one patient from Wash, DC who accomplished SO MUCH in 2022 and she has RA! @hirokonishimura https://t.co/QStFGZLsTR https://t.co/Q7GoYQYvwx

Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using Na

Social Author Name
Dr. John Cush
Tweet Content
Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl

Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX.

Social Author Name
Dr. John Cush
Tweet Content
Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/q516bZPOq5 https://t.co/2xdOa8pVAv

Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan

Social Author Name
Dr. John Cush
Tweet Content
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/m8cdJgM7UC

Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scor

Social Author Name
Dr. John Cush
Tweet Content
Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scores ≥4 (72 vs 14%) & inpatient (41 vs 17%). LUPUS FLARES were more (61 vs 54%), more severe (11 vs 5%) & twice the cost https://t.co/tXI7SSalaV https://t.co/z0SorOQilb

Medical (AKA surgical) masks are not inferior to N95 fitted masks. A study of 1009 medical workers in 4 countries carin

Social Author Name
Dr. John Cush
Tweet Content
Medical (AKA surgical) masks are not inferior to N95 fitted masks. A study of 1009 medical workers in 4 countries caring for COVID+ infected patients shows equal rate of PCR+ COVID tests (10.5% vs 9.3% +) (HR 1.14 [95% CI, 0.77 to 1.69]) https://t.co/wTuLHcOxlO https://t.co/gjqfLOU7JW

2002-2019 Canadian study of Rheumatology care: access has improved but problems exist, esp w/ DMARD use. In 112,494 new

Social Author Name
Dr. John Cush
Tweet Content
2002-2019 Canadian study of Rheumatology care: access has improved but problems exist, esp w/ DMARD use. In 112,494 new RA pts, 84% saw Rheum <1yrs w/ 43% increase by 2019. Suboptimal DMARD use in elderly improved 55 to 69% https://t.co/tpv514P0GP https://t.co/AIRuf7u60d

Do not take antacids or PPI with mycophenolate. Magnesium &amp; aluminium hydroxide antacids (Maalox) will lower MMF Cma

Social Author Name
Dr. John Cush
Tweet Content
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/D0eQWcON2J https://t.co/rK77lCmbVv https://t.co/5X0e6DBxAh https://t.co/ZpJtc8SdcG
In Giant Cell Arteritis, Hospital Admission Is Bad News

One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.

Among the cohort of 1,206 patients hospitalized with GCA in the U.S., 6-month readmission rates stood at 34%, according to Radjiv Goulabchand, MD, of CHU Nîmes in France, and colleagues.

COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at

Social Author Name
Dr. John Cush
Tweet Content
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/22DhyJUeuo
Subscribe to
×